Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT ID: NCT03255369
Last Updated: 2018-05-03
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
500 participants
Study Classification
OBSERVATIONAL
Study Start Date
2016-01-02
Study Completion Date
2019-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The recent increase in the number of cases of congenital microcephaly observed in Brazil is a reason of great concern. This increase occurred a few months after Zika virus (ZIKV) was introduced in the country, which was associated with reports of pregnant women presenting fever and rash illness during pregnancy. Thus, the hypothesis of a relationship between ZIKV infection and microcephaly became plausible. However, studies on the pathophysiology of maternal ZIKV infection, its consequences for the fetus, and the development of severe encephalopathy are still needed. Knowledge about the natural history of vertical transmission and its association with changes in fetal development in early life is still scarce. Studies on factors which determine the severity and clinical evolution, such as inflammatory response mechanisms, viral evolution, and development of serological tests to identify ZIKV infection, are still needed. The Aedes aegypti is responsible for the transmission of various types of viruses of interest to human health. Currently, it is primarily responsible for the transmission of the dengue, chikungunya, and ZIKV in epidemic proportions. In addition, it is not yet known whether there is an interaction between these viruses and whether the interaction can determine the severity of the disease. The aim of this study is to evaluate the natural history of ZIKV disease in two cohorts( pregnant women and children) starting with pregnant women or newborns or evennursing mothers, identifying risk biomarkers, mapping the anti-viral inflammatory response, evaluating the molecular evolution of the virus,which areimportant to determine the mechanisms of vertical viral infection and verify children neurodevelopment from birth to the end of 3rd year of life.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
NCT04182685
Zika Virus
COMPLETED
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
NCT02223637
Meningococcal Disease
Pregnancy
Infections, Meningococcal
COMPLETED
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
NCT07254702
Chikungunya Virus Infection
NOT_YET_RECRUITING
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis
NCT01856205
Japanese Encephalitis
COMPLETED
PHASE2
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
NCT03356561
Healthy
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The mais goal of the study is to assess the natural history of vertical ZIKV transmission from pregnancy to the end of third year of life and the existence of risk factors associated with the incidence of clinical and neurological disorders, specially microcephaly.
A longitudinal study will be conducted from gestation to the end of the third year of life, during which ZIKV infection will be the main exposure.
Sample size will be 500 children exposed to zika virus. The sample size was calculated for rare events with basis on the usual microcephaly prevalence in Brazil (2:10.000) and expected increase in the number of cases among pregnant women exposed to ZIKAV.
The study will be conducted at the Fernandes Figueira National Institute for Health of Women and Children (IFF). The pregnant women will be selected in the prenatal care clinic at IFF and in the Family Health Strategy units, at Centro de Saúde Escola Germano Sinval Faria (CDEGSF), which are both from FioCruz/RJ. We also will recruit pregnant woman from clinical family of SMS Rio de Janeiro.
Inclusion criteria The study population will be composed of pregnant women who present symptoms compatible with ZIKAV infection, with skin rash, arthralgia-associated fever, myalgia, non-purulent conjunctivitis, or headache and asymptomatic pregnant women identified at the same time of possibility of exposure. We will include patients with RT- PCR positive.
All pregnant women who are in the prenatal follow up at IFF and CSGSF, irrespective of the gestational age, are elegible as a not exposed in the beginning.
Exclusion criteria Pregnant women with chromosomal abnormalities detected during fetal life or birth will be excluded.
Definition of exposure Given the knowledge that about 80% of ZIKAV infections are asymptomatic, the exposure will be confirmed by the positivity in diagnostic tests (PCR or serological tests). Considering the future availability of serological tests, some strategies will be used to define exposure groups because up to now only the PCR test is available, which remains positive only in the acute phase of the disease.
As described above, the symptomatic women will be referred for infection diagnostic confirmation by RT-PCR , and serologic tests for dengue, chikcungunha, CMV, toxoplasmosis, and rubella.
Women with and without symptoms will have their blood sampled for serological tests in the three trimesters of pregnancy and at birth. Blood samples will be stored in a biorepository for ZIKA serological testing when specific serological tests are available. These sequential samples will also be used to validate serological tests that are in the development stage.
The exposure groups to be compared will be composed with basis on the results of the serological tests. The asymptomatic individuals whose blood samples indicate the presence of Zika infection in the future, will migrate to the group of exposed ones.
The pregnant women in the cohort presenting positive results for specific tests (PCR in the acute phase and serological tests later) will be considered exposed to infection whereas pregnant women with negative results will be considered not exposed.
This second group can be categorized as asymptomatic and symptomatic. The third group will be the normal children born from mothers without zika proved by negative IgG and IgM Each child will be followed for three years from birth onwards.
Outcomes to be analyzed The main outcome will be microcephaly and/or delay in development using Bayley Score 3rd edition at 12, 18 and 24-36 months of age.
The secondary study outcomes will be as follows: pregnancy ultrasounds status, placenta injuries, ocular, hearing, cardiac, nutritional status of children and neurodevelopmental changes from birth to three years old, death in pregnant women, abortion, fetal death, and death during the first three years of life.
Data collection:
The inclusion of pregnant women will occur in the first 24 months of the study. To identify the outcomes, each child will be followed from birth to completion of three years of chronological age. The total study period for data collection will be of 5 years. The study will be conducted in the period Jan 2016 - Mar 2022.
Data will be collected by health professionals who are linked to health services and provide assistance to the study population.
Data on gestation, birth, and the first three years of life will be obtained from an interview with each woman using a questionnaire after appointment. In addition, data for records will be collected in forms prepared for this purpose.
The data collection form (CRF/DCF) will be constructed and validated in all its dimensions among the services. POPs for the study flow diagram and for each procedure and care level will be prepared.
* Socioeconomic characteristics (education, per capita family income, housing conditions, sanitation, and garbage collection); health conditions (co-morbidities).
* History of exposure to ZIKAV: identification of relatives, neighbors, and work colleagues with Zika
Follow up of the study population
Follow up of the pregnant women:
The pregnant women included in the study will be followed in the prenatal clinic, at the Fernandes Figueira National Brazilian Institute for Health of Women and Children.
After inclusion of the pregnant women in the study, consultations will occur monthly, and exams will be performed according the following protocol:
* Fetal ultrasound at each trimester
* Serological exams for Zika, dengue, chikungunya, CMV, toxoplasmosis and rubella each trimester
* PCR for Zika virus if symptomatic pregnant woman
* Prenatal examinations as recommended by the Stork Network from Brazilian Minister of Health
* Prenatal examinations as recommended by the Brazilian Stork Network The amniotic fluid can be collected if indicated by the presence of associated congenital anomalies.
Doppler:
The umbilical cord will be insonated to obtain a sonogram of the umbilical artery and thus assess the pulsatility index (PI), resistance index (RI), and peak systolic velocity (PSV).
Virus detection in serum and other human secretions For detection of virus in patients, RNA is extracted from serum and/or urine (200 ml) using the RTP Pathogen (Stratec Biomedical AG, Birkenfeld, Germany) kit according to the manufacturer's instructions. RNA isolated serves as a template in in real-time /RT-PCRreactions asdescribed by: Lanciotti et al., 2008 e Faye et al., 2013.
Virus detection in serum and other human secretions For genomic sequencing, specific regions of the virus genome will be amplified by the RT-PCR method. The products thusobtained will be purified by agarose gel electrophoresis and then extracted from the gel using the QIAquick Gel Extraction (Qiagen) kit. After extraction, the material will be quantified in agarose gel by comparison between band intensities using the Low DNA Mass Ladder (Life Technologies) standard. The amount needed for sequencing will be forwarded to the Fiocruz sequencing platform. The sequences will be manually edited using the Bioedit (v. 7.0.5.3) program, and the phylogenetic analyses will be performed using the MEGA (v. 5:05) program.
Analysis of the placenta and immunohistochemistry The fresh placentas will be forwarded to the Department of Pathological Anatomy and Cytopathology (DAPC/DPAC) where they will be kept in the refrigerator for up to 48 h. They are described, weighed, and photographed according to the routine for analysis of placenta. Fragments from the chorionic plate, cord, and membranes will be removed and frozen in liquid nitrogen. The placental plate (five areas), cord (at least two areas), and chorion (one fragment) will be fixed in buffered formalin maximum time: 30 h). They will be then cleaved for histological processing and embedded in paraffin.
Phenotypic characterization of placental cells and maternal and umbilical cord blood and child oral swab by flow cytometry Placental fragments will be collected and maintained in sterile DMEM (Sigma; St. Louis, MO, \[USA\]) culture medium (4 °C) and cleaved into several fragments (thickness: 1-2 mm). After cleavage, they are washed in DMEM and subjected to dissociation cycles in collagenase 1A (Sigma; \_) (300 U/mg; in 1% DMEM) enzyme. Dissociation will occur in 6-8 cycles (mild agitation; 37 °C, 10 min each). The cell suspension thusobtained will be centrifuged (1000 rpm; 4 °C; 10 min) and the pellet will be placed /suspended in DMEM with fetal calf serum (FCS; 10%; Sigma; \_; 4 °C) to /inactivate /inhibit the collagenase enzyme /action /activity?. The dissociated material will \[then\] be filtered /in /through?a membrane (\[pore diameter:\] 70 mm). Then, the cells will be counted in a Neubauer chamber for use in the following procedures. The maternal and umbilical cord blood will be collected in /a blood /an appropriate tube containing EDTA as anticoagulant. The serum will be used for viral detection, and the leukocyte cells will be marked after lysis of red blood cells.\\
Necropsy of Fetuses and Stillbirths Histopathological and immunohistochemical exams and imaging morphogenesis study will be performed in brain and other organs from fetuses and stillbirths /in consequence of ZIKAV infection. Besides the usual histological processing in paraffin, the other organs will be frozen and submitted to extraction of genetic material and investigation of viral RNA. The eyeball will also be analyzed to evaluate possible ocular changes.
Follow-up of newborns:
Newborns will be followed until 3 years of age in the outpatient clinic at IFF, whose routine includes at least 6 visits in the first year, 4 visits/year in the second and third years. A multidisciplinary outpatient clinic will be established in both Unit of Infectious Diseases in Pediatrics and Pediatric Outpatient Clinic to follow the cohort of children with chance of vertical exposure to the ZIKA virus. The outpatient clinic will have medical personnel, and professionals in the areas of physical therapy, phonoaudiology, psychology, and social service. The medical team will be responsible for following the patients, in collaboration with specialties as neurology, pediatric cardiology and ophthalmology, and medical genetics service. Whenever necessary, admission of these patients to establish \[either\] the diagnosis or initial approach -{of the case} will occur in the DIPe ward.
The initial evaluation as recommended for patients either known to be exposed to the virus or with microcephaly will consist of the following exams and/or evaluations: neurological, ocular, hearing, EEG if necessary, ECG, cord blood for RT-PCR and IgM. Anthropometric data and physical examination of the newborn infant, with emphasis on precise measurement of head circumference using the Intergrowth Curve (2014) as a reference, according to gestational age and patient gender. Evaluation by the Genetics to detect dysmorphic characteristics or congenital anomalies that can compromise /affect other organs.
Imaging exams:
1. transfontanelle sonography (USTF), as first choice
2. cranial tomography (CT) without contrast, if TF is not technically possible
3. Abdominal ultrasound
4. Echocardiogram
5. Brain magnetic resonance imaging, when indicated. g) Newborn Hearing Screening (TAN):
1\. Evoked optoacoustic emissions (EOAE); 24-48 h of life 2. Auditory Evoked Potential of Brain Stem (PEATE/ABR): up to 1 month of life in children with microcephaly. In case of failure, retesting must be done within 30 days. In case of retest failure, forward \[the NB\] immediately \[to \_\].
h) Ocular Neonatal Screening (TON):
1. Inspection and Testing of retinal Red Reflection.
2. Eye Fund exam (fundoscopy)
3. Documentation with RetCam
In the subsequent consultations, the clinical follow up, PC measurement, development evaluation (including early stimulation) by physical therapy, and morbidity and mortality evaluation will be maintained. In the first year of life, PEATE will be performed every three months. The subsequent clinic visits will occur monthly until 6 months of age, every two months in the period 6-12 months, and every three months until three years \[of life\]. The ophthalmologic evaluation (funduscopic examination) will be held every return.
The neurological follow up will depend on the initial condition of the patient. Patients without microcephaly will be evaluated at birth, 30 days, and 2, 4, 6, 9, 12, 18, 24, and 36 months. Patients with microcephaly will be evaluated at birth, 30 days, and every 2 or 3 months, or more frequently if necessary.
Evaluation of motor development will be done by the Dubowitz examination (in the first 72 h), Alberta Infant Motor Scale (AIMS; every three months until the child walk or complete 18 months of life), and Bayley Test-3rd edition at 12,18 and between 12-36 months of age.
Evaluation of language development will be performed at 12, 24, and 36 months, with regard to possible effects on the neurodevelopment, cognitive development, and language skills.
A longitudinal study will be conducted from gestation to the end of the third year of life, during which ZIKV infection will be the main exposure.
Sample size will be 500 children exposed to zika virus. The sample size was calculated for rare events with basis on the usual microcephaly prevalence in Brazil (2:10.000) and expected increase in the number of cases among pregnant women exposed to ZIKAV.
The study will be conducted at the Fernandes Figueira National Institute for Health of Women and Children (IFF). The pregnant women will be selected in the prenatal care clinic at IFF and in the Family Health Strategy units, at Centro de Saúde Escola Germano Sinval Faria (CDEGSF), which are both from FioCruz/RJ. We also will recruit pregnant woman from clinical family of SMS Rio de Janeiro.
Inclusion criteria The study population will be composed of pregnant women who present symptoms compatible with ZIKAV infection, with skin rash, arthralgia-associated fever, myalgia, non-purulent conjunctivitis, or headache and asymptomatic pregnant women identified at the same time of possibility of exposure. We will include patients with RT- PCR positive.
All pregnant women who are in the prenatal follow up at IFF and CSGSF, irrespective of the gestational age, are elegible as a not exposed in the beginning.
Exclusion criteria Pregnant women with chromosomal abnormalities detected during fetal life or birth will be excluded.
Definition of exposure Given the knowledge that about 80% of ZIKAV infections are asymptomatic, the exposure will be confirmed by the positivity in diagnostic tests (PCR or serological tests). Considering the future availability of serological tests, some strategies will be used to define exposure groups because up to now only the PCR test is available, which remains positive only in the acute phase of the disease.
As described above, the symptomatic women will be referred for infection diagnostic confirmation by RT-PCR , and serologic tests for dengue, chikcungunha, CMV, toxoplasmosis, and rubella.
Women with and without symptoms will have their blood sampled for serological tests in the three trimesters of pregnancy and at birth. Blood samples will be stored in a biorepository for ZIKA serological testing when specific serological tests are available. These sequential samples will also be used to validate serological tests that are in the development stage.
The exposure groups to be compared will be composed with basis on the results of the serological tests. The asymptomatic individuals whose blood samples indicate the presence of Zika infection in the future, will migrate to the group of exposed ones.
The pregnant women in the cohort presenting positive results for specific tests (PCR in the acute phase and serological tests later) will be considered exposed to infection whereas pregnant women with negative results will be considered not exposed.
This second group can be categorized as asymptomatic and symptomatic. The third group will be the normal children born from mothers without zika proved by negative IgG and IgM Each child will be followed for three years from birth onwards.
Outcomes to be analyzed The main outcome will be microcephaly and/or delay in development using Bayley Score 3rd edition at 12, 18 and 24-36 months of age.
The secondary study outcomes will be as follows: pregnancy ultrasounds status, placenta injuries, ocular, hearing, cardiac, nutritional status of children and neurodevelopmental changes from birth to three years old, death in pregnant women, abortion, fetal death, and death during the first three years of life.
Data collection:
The inclusion of pregnant women will occur in the first 24 months of the study. To identify the outcomes, each child will be followed from birth to completion of three years of chronological age. The total study period for data collection will be of 5 years. The study will be conducted in the period Jan 2016 - Mar 2022.
Data will be collected by health professionals who are linked to health services and provide assistance to the study population.
Data on gestation, birth, and the first three years of life will be obtained from an interview with each woman using a questionnaire after appointment. In addition, data for records will be collected in forms prepared for this purpose.
The data collection form (CRF/DCF) will be constructed and validated in all its dimensions among the services. POPs for the study flow diagram and for each procedure and care level will be prepared.
* Socioeconomic characteristics (education, per capita family income, housing conditions, sanitation, and garbage collection); health conditions (co-morbidities).
* History of exposure to ZIKAV: identification of relatives, neighbors, and work colleagues with Zika
Follow up of the study population
Follow up of the pregnant women:
The pregnant women included in the study will be followed in the prenatal clinic, at the Fernandes Figueira National Brazilian Institute for Health of Women and Children.
After inclusion of the pregnant women in the study, consultations will occur monthly, and exams will be performed according the following protocol:
* Fetal ultrasound at each trimester
* Serological exams for Zika, dengue, chikungunya, CMV, toxoplasmosis and rubella each trimester
* PCR for Zika virus if symptomatic pregnant woman
* Prenatal examinations as recommended by the Stork Network from Brazilian Minister of Health
* Prenatal examinations as recommended by the Brazilian Stork Network The amniotic fluid can be collected if indicated by the presence of associated congenital anomalies.
Doppler:
The umbilical cord will be insonated to obtain a sonogram of the umbilical artery and thus assess the pulsatility index (PI), resistance index (RI), and peak systolic velocity (PSV).
Virus detection in serum and other human secretions For detection of virus in patients, RNA is extracted from serum and/or urine (200 ml) using the RTP Pathogen (Stratec Biomedical AG, Birkenfeld, Germany) kit according to the manufacturer's instructions. RNA isolated serves as a template in in real-time /RT-PCRreactions asdescribed by: Lanciotti et al., 2008 e Faye et al., 2013.
Virus detection in serum and other human secretions For genomic sequencing, specific regions of the virus genome will be amplified by the RT-PCR method. The products thusobtained will be purified by agarose gel electrophoresis and then extracted from the gel using the QIAquick Gel Extraction (Qiagen) kit. After extraction, the material will be quantified in agarose gel by comparison between band intensities using the Low DNA Mass Ladder (Life Technologies) standard. The amount needed for sequencing will be forwarded to the Fiocruz sequencing platform. The sequences will be manually edited using the Bioedit (v. 7.0.5.3) program, and the phylogenetic analyses will be performed using the MEGA (v. 5:05) program.
Analysis of the placenta and immunohistochemistry The fresh placentas will be forwarded to the Department of Pathological Anatomy and Cytopathology (DAPC/DPAC) where they will be kept in the refrigerator for up to 48 h. They are described, weighed, and photographed according to the routine for analysis of placenta. Fragments from the chorionic plate, cord, and membranes will be removed and frozen in liquid nitrogen. The placental plate (five areas), cord (at least two areas), and chorion (one fragment) will be fixed in buffered formalin maximum time: 30 h). They will be then cleaved for histological processing and embedded in paraffin.
Phenotypic characterization of placental cells and maternal and umbilical cord blood and child oral swab by flow cytometry Placental fragments will be collected and maintained in sterile DMEM (Sigma; St. Louis, MO, \[USA\]) culture medium (4 °C) and cleaved into several fragments (thickness: 1-2 mm). After cleavage, they are washed in DMEM and subjected to dissociation cycles in collagenase 1A (Sigma; \_) (300 U/mg; in 1% DMEM) enzyme. Dissociation will occur in 6-8 cycles (mild agitation; 37 °C, 10 min each). The cell suspension thusobtained will be centrifuged (1000 rpm; 4 °C; 10 min) and the pellet will be placed /suspended in DMEM with fetal calf serum (FCS; 10%; Sigma; \_; 4 °C) to /inactivate /inhibit the collagenase enzyme /action /activity?. The dissociated material will \[then\] be filtered /in /through?a membrane (\[pore diameter:\] 70 mm). Then, the cells will be counted in a Neubauer chamber for use in the following procedures. The maternal and umbilical cord blood will be collected in /a blood /an appropriate tube containing EDTA as anticoagulant. The serum will be used for viral detection, and the leukocyte cells will be marked after lysis of red blood cells.\\
Necropsy of Fetuses and Stillbirths Histopathological and immunohistochemical exams and imaging morphogenesis study will be performed in brain and other organs from fetuses and stillbirths /in consequence of ZIKAV infection. Besides the usual histological processing in paraffin, the other organs will be frozen and submitted to extraction of genetic material and investigation of viral RNA. The eyeball will also be analyzed to evaluate possible ocular changes.
Follow-up of newborns:
Newborns will be followed until 3 years of age in the outpatient clinic at IFF, whose routine includes at least 6 visits in the first year, 4 visits/year in the second and third years. A multidisciplinary outpatient clinic will be established in both Unit of Infectious Diseases in Pediatrics and Pediatric Outpatient Clinic to follow the cohort of children with chance of vertical exposure to the ZIKA virus. The outpatient clinic will have medical personnel, and professionals in the areas of physical therapy, phonoaudiology, psychology, and social service. The medical team will be responsible for following the patients, in collaboration with specialties as neurology, pediatric cardiology and ophthalmology, and medical genetics service. Whenever necessary, admission of these patients to establish \[either\] the diagnosis or initial approach -{of the case} will occur in the DIPe ward.
The initial evaluation as recommended for patients either known to be exposed to the virus or with microcephaly will consist of the following exams and/or evaluations: neurological, ocular, hearing, EEG if necessary, ECG, cord blood for RT-PCR and IgM. Anthropometric data and physical examination of the newborn infant, with emphasis on precise measurement of head circumference using the Intergrowth Curve (2014) as a reference, according to gestational age and patient gender. Evaluation by the Genetics to detect dysmorphic characteristics or congenital anomalies that can compromise /affect other organs.
Imaging exams:
1. transfontanelle sonography (USTF), as first choice
2. cranial tomography (CT) without contrast, if TF is not technically possible
3. Abdominal ultrasound
4. Echocardiogram
5. Brain magnetic resonance imaging, when indicated. g) Newborn Hearing Screening (TAN):
1\. Evoked optoacoustic emissions (EOAE); 24-48 h of life 2. Auditory Evoked Potential of Brain Stem (PEATE/ABR): up to 1 month of life in children with microcephaly. In case of failure, retesting must be done within 30 days. In case of retest failure, forward \[the NB\] immediately \[to \_\].
h) Ocular Neonatal Screening (TON):
1. Inspection and Testing of retinal Red Reflection.
2. Eye Fund exam (fundoscopy)
3. Documentation with RetCam
In the subsequent consultations, the clinical follow up, PC measurement, development evaluation (including early stimulation) by physical therapy, and morbidity and mortality evaluation will be maintained. In the first year of life, PEATE will be performed every three months. The subsequent clinic visits will occur monthly until 6 months of age, every two months in the period 6-12 months, and every three months until three years \[of life\]. The ophthalmologic evaluation (funduscopic examination) will be held every return.
The neurological follow up will depend on the initial condition of the patient. Patients without microcephaly will be evaluated at birth, 30 days, and 2, 4, 6, 9, 12, 18, 24, and 36 months. Patients with microcephaly will be evaluated at birth, 30 days, and every 2 or 3 months, or more frequently if necessary.
Evaluation of motor development will be done by the Dubowitz examination (in the first 72 h), Alberta Infant Motor Scale (AIMS; every three months until the child walk or complete 18 months of life), and Bayley Test-3rd edition at 12,18 and between 12-36 months of age.
Evaluation of language development will be performed at 12, 24, and 36 months, with regard to possible effects on the neurodevelopment, cognitive development, and language skills.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
ZIKA VIRUS INFECTION
Child Development
Microcephaly
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Child exposed Zika virus proved
child born to mothers with proved zika virus in pregnancy by RT-PCR
Child exposed Zika virus proved
Intervention Type
OTHER
There will be applied Bayley Teste 3rd edition
Child exposed to zika virus suspected
Child born with symptoms similar to babies proved exposed to zika virus but mothers without symptoms or positive RT-PCR
Child exposed Zika virus proved
Intervention Type
OTHER
There will be applied Bayley Teste 3rd edition
Normal Child
Normal child from mothers without Zika (IgG and IgM negative)
Child exposed Zika virus proved
Intervention Type
OTHER
There will be applied Bayley Teste 3rd edition
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Child exposed Zika virus proved
There will be applied Bayley Teste 3rd edition
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Child exposed Zika virus suspected
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
The study population will be composed of pregnant women who present symptoms compatible with ZIKAV infection, with skin rash, arthralgia-associated fever, myalgia, non-purulent conjunctivitis, or headache and asymptomatic pregnant women identified at the same time of possibility of exposure. We will include patients with RT- PCR positive.
All pregnant women who are in the prenatal follow up at IFF and CSGSF, irrespective of the gestational age, are elegible as a not exposed in the beginning.
Children born during the outbreak by mothers with confirmed infection, suspected infection and normal pregnancy
All pregnant women who are in the prenatal follow up at IFF and CSGSF, irrespective of the gestational age, are elegible as a not exposed in the beginning.
Children born during the outbreak by mothers with confirmed infection, suspected infection and normal pregnancy
Exclusion Criteria
Pregnant women with chromosomal abnormalities detected during fetal life or birth will be excluded.
\-
\-
Minimum Eligible Age
2 Days
Maximum Eligible Age
3 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Conselho Nacional de Desenvolvimento Científico e Tecnológico
OTHER_GOV
Sponsor Role
collaborator
Rio de Janeiro State Research Supporting Foundation (FAPERJ)
OTHER_GOV
Sponsor Role
collaborator
Oswaldo Cruz Foundation
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maria E Moreira, MD
Role: PRINCIPAL_INVESTIGATOR
Fundação Oswaldo Cruz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Fernandes Figueira/Fiocruz
Rio de Janeiro, Rio de Janeiro, Brazil
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Brazil
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Brasil P, Pereira JP Jr, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, Rabello RS, Valderramos SG, Halai UA, Salles TS, Zin AA, Horovitz D, Daltro P, Boechat M, Raja Gabaglia C, Carvalho de Sequeira P, Pilotto JH, Medialdea-Carrera R, Cotrim da Cunha D, Abreu de Carvalho LM, Pone M, Machado Siqueira A, Calvet GA, Rodrigues Baiao AE, Neves ES, Nassar de Carvalho PR, Hasue RH, Marschik PB, Einspieler C, Janzen C, Cherry JD, Bispo de Filippis AM, Nielsen-Saines K. Zika Virus Infection in Pregnant Women in Rio de Janeiro. N Engl J Med. 2016 Dec 15;375(24):2321-2334. doi: 10.1056/NEJMoa1602412. Epub 2016 Mar 4.
Reference Type
BACKGROUND
Chimelli L, Melo ASO, Avvad-Portari E, Wiley CA, Camacho AHS, Lopes VS, Machado HN, Andrade CV, Dock DCA, Moreira ME, Tovar-Moll F, Oliveira-Szejnfeld PS, Carvalho ACG, Ugarte ON, Batista AGM, Amorim MMR, Melo FO, Ferreira TA, Marinho JRL, Azevedo GS, Leal JIBF, da Costa RFM, Rehen S, Arruda MB, Brindeiro RM, Delvechio R, Aguiar RS, Tanuri A. The spectrum of neuropathological changes associated with congenital Zika virus infection. Acta Neuropathol. 2017 Jun;133(6):983-999. doi: 10.1007/s00401-017-1699-5. Epub 2017 Mar 22.
Reference Type
BACKGROUND
Halai UA, Nielsen-Saines K, Moreira ML, de Sequeira PC, Junior JPP, de Araujo Zin A, Cherry J, Gabaglia CR, Gaw SL, Adachi K, Tsui I, Pilotto JH, Nogueira RR, de Filippis AMB, Brasil P. Maternal Zika Virus Disease Severity, Virus Load, Prior Dengue Antibodies, and Their Relationship to Birth Outcomes. Clin Infect Dis. 2017 Sep 15;65(6):877-883. doi: 10.1093/cid/cix472.
Reference Type
BACKGROUND
Zin AA, Tsui I, Rossetto J, Vasconcelos Z, Adachi K, Valderramos S, Halai UA, Pone MVDS, Pone SM, Silveira Filho JCB, Aibe MS, da Costa ACC, Zin OA, Belfort R Jr, Brasil P, Nielsen-Saines K, Moreira MEL. Screening Criteria for Ophthalmic Manifestations of Congenital Zika Virus Infection. JAMA Pediatr. 2017 Sep 1;171(9):847-854. doi: 10.1001/jamapediatrics.2017.1474.
Reference Type
RESULT
Tiene SF, Cranston JS, Nielsen-Saines K, Kerin T, Fuller T, Vasconcelos Z, Marschik PB, Zhang D, Pone M, Pone S, Zin A, Brickley E, Orofino D, Brasil P, Adachi K, da Costa ACC, Lopes Moreira ME. Early Predictors of Poor Neurologic Outcomes in a Prospective Cohort of Infants With Antenatal Exposure to Zika Virus. Pediatr Infect Dis J. 2022 Mar 1;41(3):255-262. doi: 10.1097/INF.0000000000003379.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
52675616.0.0000.5269
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
NCT07347002
NOT_YET_RECRUITING
Chikungunya Virus Vaccine Trial in Healthy Adults
NCT01489358
COMPLETED
PHASE1
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
NCT06334393
ACTIVE_NOT_RECRUITING
PHASE1
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
NCT02531698
COMPLETED
PHASE2
Neurologic Manifestations of the Arbovirus Infection in Colombia
NCT03206541
COMPLETED
A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants
NCT02367664
COMPLETED
PHASE3
Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects
NCT03014089
COMPLETED
PHASE1
A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa
NCT05868733
RECRUITING
PHASE2
A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children.
NCT07003984
RECRUITING
PHASE3
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
NCT03879603
COMPLETED
PHASE1
Maternal Immunization With MenAfriVac™
NCT03746665
UNKNOWN
PHASE3
A Case-control Study of the Efficacy of a New Serogroup A Meningococcal Conjugate Vaccine (MenAfriVac) in Mali and Niger
NCT01303211
WITHDRAWN
Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.
NCT02534935
COMPLETED
PHASE2
Vaccine to Prevent West Nile Virus Disease
NCT00106769
COMPLETED
PHASE1
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
NCT00667602
COMPLETED
PHASE3
Diagnostics and Surveillance of Acute Meningo-encephalitis Among Children in Cambodia With a Focus on Japanese Encephalitis Virus
NCT06674837
NOT_YET_RECRUITING
Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America
NCT01187433
COMPLETED
PHASE2
A Real-world Evidence Study of BNT162b2 mRNA Covid-19 Vaccine Among Children in Brazil
NCT05403307
COMPLETED
Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage
NCT01119482
COMPLETED
PHASE4
Conjugate Vaccine Against Meningococcus C a Brazilian Project
NCT02858570
UNKNOWN
PHASE2/PHASE3
A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years
NCT01352793
COMPLETED
PHASE3
Correlation Between Cytokines and the Severity of Meningococcal Disease
NCT01133834
COMPLETED
Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children
NCT02990182
UNKNOWN
Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age
NCT02919293
UNKNOWN
PHASE1/PHASE2